期刊
HUMAN MOLECULAR GENETICS
卷 24, 期 8, 页码 2274-2286出版社
OXFORD UNIV PRESS
DOI: 10.1093/hmg/ddu745
关键词
-
资金
- Fonds Erasme Olivia De Clercq, Belgium
- Phillip Bennett and Kyle Bryant Translational Research Award of the Friedreich Ataxia Research Alliance, USA
- European Union (European Community)
- Actions de Recherche Concertee de la Communaute Francaise (ARC)
- Fonds National de la Recherche Scientifique (FNRS), Belgium
Friedreich's ataxia (FRDA) is a neurodegenerative disorder associated with cardiomyopathy and diabetes. Effective therapies for FRDA are an urgent unmet need; there are currently no options to prevent or treat this orphan disease. FRDA is caused by reduced expression of the mitochondrial protein frataxin. We have previously demonstrated that pancreatic beta-cell dysfunction and death cause diabetes in FRDA. This is secondary to mitochondrial dysfunction and apoptosis but the underlying molecular mechanisms are not known. Here we show that beta-cell demise in frataxin deficiency is the consequence of oxidative stress-mediated activation of the intrinsic pathway of apoptosis. The pro-apoptotic Bcl-2 family members Bad, DP5 and Bim are the key mediators of frataxin deficiency-induced beta-cell death. Importantly, the intrinsic pathway of apoptosis is also activated in FRDA patients' induced pluripotent stem cell-derived neurons. Interestingly, cAMP induction normalizes mitochondrial oxidative status and fully prevents activation of the intrinsic pathway of apoptosis in frataxin-deficient beta-cells and neurons. This preclinical study suggests that incretin analogs hold potential to prevent/delay both diabetes and neurodegeneration in FRDA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据